TSHA - CIK 0001806310
Taysha Gene Therapies, Inc. (TSHA) reported revenue of $9.77M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $9.77M | +17.3% |
| FY 2024 | $8.33M | -46.1% |
| FY 2023 | $15.45M | +517.5% |
| FY 2022 | $2.50M | - |
Taysha Gene Therapies, Inc. (TSHA) reported revenue of $9.77M for fiscal year 2025, as filed in its audited annual report with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.